Join

Compare · ACLX vs ARGX

ACLX vs ARGX

Side-by-side comparison of Arcellx Inc. (ACLX) and argenx SE (ARGX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ACLX and ARGX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • ARGX is the larger of the two at $54.76B, about 8.1x ACLX ($6.73B).
  • Over the past year, ACLX is up 72.0% and ARGX is up 51.2% - ACLX leads by 20.8 points.
  • ARGX has hit the wire 5 times in the past 4 weeks while ACLX has been quiet.
  • ARGX has more recent analyst coverage (25 ratings vs 24 for ACLX).
PerformanceACLX+72.01%ARGX+54.55%
2025-06-09+0.00%2026-04-27
MetricACLXARGX
Company
Arcellx Inc.
argenx SE
Price
$115.05+0.02%
$882.63-1.03%
Market cap
$6.73B
$54.76B
1M return
+0.38%
+12.11%
1Y return
+72.01%
+51.24%
Sector
Health Care
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2022
2017
News (4w)
0
5
Recent ratings
24
25
ACLX

Arcellx Inc.

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

ARGX

argenx SE

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

Latest ACLX

Latest ARGX